Hemotec, Inc.

Cynthia A Taylor

Robert F Baugh

An inhibitor of platelet-related procoagulant activity is included in a collection medium into which a whole blood sample is collected. The inhibitor prevents an initial drop in the recalcified activated clotting time measured during an assay test conducted on the whole blood sample collected in citrate in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of the procoagulant activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of this platelet-related procoagulant activity.

Method of collecting and analyzing a sample of blood when monitoring

An inhibitor of Platelet Factor 3 activity is included in a collection medium into which a whole blood sample is a collected. The inhibitor of Platelet Factor 3 activity, it has been discovered, prevents an initial drop in the activated clotting time measured during an assay test conducted on the whole blood sample collected in the medium. The discovery of the problem of the initial drop in the activated clotting time and the solution of including the inhibitor of Platelet Factor 3 activity is of considerable importance in heparin therapy, since the initial drop in the activated clotting time of heparinized blood is substantial. The inhibitor of Platelet Factor 3 activity can be included with a calcium chelating agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet thromboxane A2 synthesis, are effective inhibitors of Platelet Factor 3 activity.

Growing community of inventors

Denver, CO, United States of America

Cynthia A Taylor